Perspective Therapeutics(CATX) Newsfilter·2025-03-26 20:10Core Insights - Perspective Therapeutics, Inc. is advancing its clinical-stage proprietary medicines based on a next-generation targeted radiopharmaceutical technology platform, with multiple clinical updates expected through mid-2026 [2][6][41] Clinical Programs - The company is conducting a Phase 1/2a trial of [212Pb]VMT-α-NET for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors, having received Fast Track Designation from the FDA [3][4][6] - As of February 2025, 30 patients have been enrolled in Cohort 2 of the trial, with no dose-limiting toxicities observed [6][14] - The company has achieved first-in-human combination dosing of a PD-1 inhibitor with its potential new medicine, VMT01, and has cleared an IND for PSV359, targeting FAP-α in solid tumors, with first patient dosing expected in mid-2025 [6][18][19] Financial Performance - For the year ended December 31, 2024, the company reported a net loss of 1.23 per share, compared to a net loss of 1.74 per share, for 2023 [40][49] - Research and development expenses increased by approximately 95% to 227 million as of December 31, 2024, expected to fund operations into late 2026 [31][32] Manufacturing and Operations - The company is expanding its manufacturing capabilities by establishing a regional network of drug-product finishing facilities, with a second facility in Somerset, New Jersey, commencing shipments in Q4 2024 [21][23] - The company has procured three buildings for manufacturing program candidates, with ongoing modifications and equipment installations [30] Strategic Developments - The company divested its brachytherapy business in Q2 2024, which included radioactive Cesium-131 seed assets, to focus on its core radiopharmaceutical development [28] - The patent portfolio was strengthened in 2024 with the issuance of two patents related to key assets, expiring in 2037 and 2039 [27]